A Phase 2 interventional study of Trastuzumab Deruxtecan in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma, sponsored by AstraZeneca. Completed at 24 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-21.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Adenocarcinoma with a site in China — 33 open to participants now, 42 under way, 12 of them phase 3. Adenocarcinoma · China.
Among the 77 studies in Adenocarcinoma with a site in China, this one is the 35th largest by enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2021, is one of 26 in phase 2, and was the 39th registered.
620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.
Browse Adenocarcinoma studies →33 of the 77 studies in Adenocarcinoma with a site in China are open now. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in China, United States, Japan and 1 more country
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 55+ · Men only
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Australia and 21 more countries
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 37 · Phase 3 21 · Phase 4 4
First in 2006; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 57 across 490 interventional studies indexed under Adenocarcinoma.
Median enrollment 98 across the 68 interventional studies, 250 across the 9 observational. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 77 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 7 studies filed under Adenocarcinoma — fewer than ten, so there is no comparison to draw.
9 of the studies in Adenocarcinoma with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04208347Phase 3Ruijin HospitalPerioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer | 2026-12 |
| NCT06177041Phase 3FutureGen Biopharmaceutical (Beijing) Co., LtdM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. | 2027-01-11 |
| NCT07363382First Affiliated Hospital of Fujian Medical UniversityThe Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | 2026-12-31 |
| NCT07444983Fujian Medical University Union HospitalRezvilutamide for High-Risk Prostate Cancer After Surgery | 2027-02-11 |
| NCT06926374Chinese University of Hong KongProspective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 77 studies in Adenocarcinoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior regimens including a fluoropyrimidine agent and a platinum agent
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T-DXd monotherapy
Drug: Trastuzumab Deruxtecan
Trastuzumab deruxtecan (T-DXd) by intravenous infusion
Also known as: DS8201a; AZD4552; T-DXd
Confirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)
Confirmed ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months
Best Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)
The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months
Progression-free Survival (PFS) Based on Independent Central Review (ICR)
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months
Progression-free Survival (PFS) Rate at 3 Months Based on Independent Central Review (ICR)
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 3 months using the Kaplan-Meier technique
Progression-free Survival (PFS) Rate at 6 Months Based on Independent Central Review (ICR)
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 6 months using the Kaplan-Meier technique
Progression-free Survival (PFS) Rate at 9 Months Based on Independent Central Review (ICR)
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 9 months using the Kaplan-Meier technique
Progression-free Survival (PFS) Rate at 12 Months Based on Independent Central Review (ICR)
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 12 months using the Kaplan-Meier technique
Progression-free Survival (PFS) Rate at 15 Months Based on Independent Central Review (ICR)
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 15 months using the Kaplan-Meier technique
Progression-free Survival (PFS) Rate at 18 Months Based on Independent Central Review (ICR)
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 18 months using the Kaplan-Meier technique
Progression-free Survival (PFS) Rate at 21 Months Based on Independent Central Review (ICR)
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 21 months using the Kaplan-Meier technique
Disease Control Rate (DCR) Based on Independent Central Review (ICR)
Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD)
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months
Disease Control Rate (DCR) Based on Independent Central Review (ICR) at Week 12
Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD) for at least 11 weeks (ie 12 weeks - 1 week to allow for an early assessment within the assessment window)
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. DCR assessed at Week 12
Duration of Response (DoR) Based on Independent Central Review (ICR)
DoR defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) or death in the absence of progression based on investigator assessments by using RECIST version 1.1
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months
Overall Survival (OS) Based on Independent Central Review (ICR)
OS based on ICR is defined as the time from date of enrolment until the date of death due to any cause
Time frame: From date of enrolment until death due to any cause. Assessed up to approximately 30 months (from date of first subject in to data cut-off 28February2024)
Best Percentage Change in Sum of Diameters of Measurable Tumours Based on Independent Central Review (ICR)
Best percentage change based on ICR is defined as the best change in target lesion tumour size from baseline (maximum reduction or minimum increase from baseline in the absence of a reduction)
Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months
| Milestone | T-DXd Arm |
|---|---|
| Started | 95 |
| Received treatment | 95 |
| Completed | 15 |
| Not completed | 80 |
| Withdrew: Death | 77 |
| Withdrew: Lost to follow-up | 3 |
Confirmed ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.
| Percentage of Participants | T-DXd Arm |
|---|---|
| Confirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR) | 28.8 (18.8 to 40.6) |
The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression
| Participants | T-DXd Arm |
|---|---|
| Complete response (confirmed after at least 4 weeks) | 1 |
| Partial response (confirmed after at least 4 weeks) | 20 |
| Stable disease | 37 |
| Progression | 14 |
| Not evaluable | 1 |
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
| Months | T-DXd Arm |
|---|---|
| Progression-free Survival (PFS) Based on Independent Central Review (ICR) | 5.7 (4.0 to 6.8) |
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
| Percentage of participants | T-DXd Arm |
|---|---|
| Progression-free Survival (PFS) Rate at 3 Months Based on Independent Central Review (ICR) | 69.0 (56.8 to 78.4) |
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
| Percentage of participants | T-DXd Arm |
|---|---|
| Progression-free Survival (PFS) Rate at 6 Months Based on Independent Central Review (ICR) | 43.4 (30.8 to 55.3) |
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
| Percentage of participants | T-DXd Arm |
|---|---|
| Progression-free Survival (PFS) Rate at 9 Months Based on Independent Central Review (ICR) | 27.1 (16.2 to 39.3) |
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
| Percentage of participants | T-DXd Arm |
|---|---|
| Progression-free Survival (PFS) Rate at 12 Months Based on Independent Central Review (ICR) | 16.7 (8.0 to 28.1) |
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
| Percentage of participants | T-DXd Arm |
|---|---|
| Progression-free Survival (PFS) Rate at 15 Months Based on Independent Central Review (ICR) | 11.9 (4.7 to 22.8) |
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
| Percentage of participants | T-DXd Arm |
|---|---|
| Progression-free Survival (PFS) Rate at 18 Months Based on Independent Central Review (ICR) | 4.0 (0.4 to 15.6) |
PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression
| Percentage of participants | T-DXd Arm |
|---|---|
| Progression-free Survival (PFS) Rate at 21 Months Based on Independent Central Review (ICR) | 4.0 (0.4 to 15.6) |
Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD)
| Percentage of participants | T-DXd Arm |
|---|---|
| Disease Control Rate (DCR) Based on Independent Central Review (ICR) | 79.5 (68.4 to 88.0) |
Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD) for at least 11 weeks (ie 12 weeks - 1 week to allow for an early assessment within the assessment window)
| Percentage of participants | T-DXd Arm |
|---|---|
| Disease Control Rate (DCR) Based on Independent Central Review (ICR) at Week 12 | 74.0 (62.4 to 83.5) |
DoR defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) or death in the absence of progression based on investigator assessments by using RECIST version 1.1
| Months | T-DXd Arm |
|---|---|
| Duration of Response (DoR) Based on Independent Central Review (ICR) | 6.7 (4.6 to 8.8) |
OS based on ICR is defined as the time from date of enrolment until the date of death due to any cause
| Months | T-DXd Arm |
|---|---|
| Overall Survival (OS) Based on Independent Central Review (ICR) | 11.1 (7.7 to 13.7) |
Best percentage change based on ICR is defined as the best change in target lesion tumour size from baseline (maximum reduction or minimum increase from baseline in the absence of a reduction)
| Percentage Change | T-DXd Arm |
|---|---|
| Best Percentage Change in Sum of Diameters of Measurable Tumours Based on Independent Central Review (ICR) | -22.55 ± 29.682 |
Collected over From the signature of the informed consent form until 40 (+7) days after the last dose of study treatment or until the start of the first subsequent anticancer therapy after discontinuation of study treatment, whichever comes first (maximum treatment duration of 19.3 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T-DXd | 77/95 (81.1%) | 40/95 (42.1%) | 93/95 (97.9%) |
| Event | T-DXd |
|---|---|
| Platelet count decreasedInvestigations | 6/95 |
| AnaemiaBlood and lymphatic system disorders | 5/95 |
| Covid-19Infections and infestations | 5/95 |
| PneumoniaInfections and infestations | 5/95 |
| AstheniaGeneral disorders | 4/95 |
| Covid-19 pneumoniaInfections and infestations | 4/95 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 3/95 |
| Hepatic function abnormalHepatobiliary disorders | 2/95 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/95 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/95 |
| Event | T-DXd |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 73/95 |
| White blood cell count decreasedInvestigations | 69/95 |
| Neutrophil count decreasedInvestigations | 58/95 |
| Platelet count decreasedInvestigations | 50/95 |
| NauseaGastrointestinal disorders | 41/95 |
| Decreased appetiteMetabolism and nutrition disorders | 38/95 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 37/95 |
| Aspartate aminotransferase increasedInvestigations | 30/95 |
| VomitingGastrointestinal disorders | 30/95 |
| Weight decreasedInvestigations | 27/95 |
| Age, Continuous(Years) | T-DXd Arm |
|---|---|
| Median | 60 (28 to 77) |
| Sex: Female, Male(Participants) | T-DXd Arm |
|---|---|
| Female | 22 |
| Male | 73 |
| Ethnicity (NIH/OMB)(Participants) | T-DXd Arm |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 95 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | T-DXd Arm |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 95 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . A Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2021 to primary completion in Jun 2023, 21 months.
Results were first posted in Nov 2024, 1 year 5 months after primary completion.
Of 93 phase 2 interventional studies under Adenocarcinoma, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 82. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan